← Back to Search

Virus Therapy

CDK-002 for Solid Tumors

Phase 1 & 2
Waitlist Available
Led By Roger Cohen, MD
Research Sponsored by Codiak BioSciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called CDK-002 for patients with advanced cancers that haven't responded to other treatments. The drug is injected directly into the tumor to try to shrink it or stop its growth. Flavopiridol is the first CDK inhibitor to enter clinical trials.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine the safety and tolerability of ascending doses of CDK-002

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CDK-002Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CDK-002
2020
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Codiak BioSciencesLead Sponsor
2 Previous Clinical Trials
11 Total Patients Enrolled
Roger Cohen, MDPrincipal InvestigatorUniversity of Pennsylvania Hospital
4 Previous Clinical Trials
233 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top